12 Nov 2009
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”), announces that on November 2, 2009 the following Persons Discharging Managerial Responsibility were granted options over American Depository Shares (“ADSs”) in the Company pursuant to the Shire Employee Stock Purchase Plan. The options are exercisable over the number of ADSs that may be purchased at the end of a 12 month saving period with the fortnightly savings made. The option price is the lower of 85% of the fair market value of the Company’s ADSs on November 1, 2009, being $45.31, and 85% of the fair market value of the Company’s ADSs on October 31, 2010. The options are normally exercisable on October 31, 2010.
Deputy Company Secretary
For further information please contact:
Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Eric Rojas (North America) +1 617 551 9715
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.